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Interleukin 6 is an autocrine growth factor for mesangial cells. Inter-
leukin 6 (IL-6) induces the acute phase response, differentiation of B
cells, proliferation of T cells, thymocytes, hematopoietic progenitors,
hybridoma and plasmacytoma cells. Monocytes, T cells, fibroblasts,
epithelial and endothelial cells secrete IL-6. Since IL-6 responsive
cell-types may participate in the pathogenesis of glomerular inflamma-
tion, we studied the secretion of IL-6 by rat MCs, using the IL-6
dependent hybridoma cell line B9. The results of our studies indicate
that MCs secrete IL-6 with a molecular weight of 17-42 kDa and
isoelectric point of 4.0 to 5.3. MC-IL-6 activity could be blocked by a
polyclonal antimurine-IL-6 antibody. MC express IL-6 mRNA as deter-
mined by Northern blot. Furthermore, our data demonstrate that IL-6 acts
as an autocrine growth factor for MC. Incubation of subconfluent MC with
recombinant IL-6 results in a dose-dependent increase of 3H-thymidine
incorporation and number of MCs. Moreover, reverse phase HPLC
fractions of MC-CM containing IL-6 activity increase 3H-thymidine incor-
poration by MC. In addition to its possible paracrine role in mediating the
immune response in the glomerulus, MC-IL-6 may also be one of the
autocrine signals leading to mesangial cell proliferation in vivo.
Hypercellularity and accumulation of extracellular matrix
within the glomerulus are hallmarks of glomerular diseases. The
mesangium is involved in most of these pathologic processes
[1]. Intraglomerular hypercellularity results from accumulation
of infiltrating monocyte/macrophages and T lymphocytes as
well as the proliferation of mesangial cells (MC) [2—fl]. Although
T cells represent only a minor proportion of glomerular leuko-
cytes [61, the consequences of their presence can be consider-
able as illustrated by in vivo studies showing that experimental
glomerulonephritis in chickens can be induced by transfer of T
cells from nephritic animals [71 and that suppression of T cell
function by cyclosporin A blocks the subsequent development
of glomerular lesions in acute serum sickness nephritis [8]. The
regulation of T cell function as well as T cell proliferation are
dependent on the presence of accessory antigen-presenting
cells and cytokines [9]. In addition to interleukin I (IL-l),
interleukin 6 (IL-6) is a co-stimulant for T lymphocytes [10].
The effects of IL-6 on T cells can be mediated through an IL-2
dependent as well as IL-2 independent pathway [11—13] and
IL-6 may act in the early phases of the T cell response [13].
In addition to its role in the activation of I cells, IL-6,
previously known as B cell stimulatory factor 2, hepatocyte
stimulating factor (HSF), hybridoma/plasmacytoma growth fac-
tor (HP-GF), 26-kDa protein, and interferon-beta 2 (IFN-Beta
2), has emerged as a pluripotent cytokine [14—20]. IL-6 acts
synergistically with IL-3 on the growth of early hematopoietic
progenitor colonies [21], induces growth of hybndoma and
plasmacytoma cells [16—18] and may also play a role in thymo-
cyte development [22]. In contrast, IL-6 inhibits growth of
certain neoplastic cells in vitro [23]. Additional immunologic
effects of IL-6 include the induction of the acute phase response
by the liver [15] and differentiation of B cells into antibody
secreting cells [14]. In addition to monocyte/macrophages [24]
and T cells [18], cells of epithelial [25], endothelial [26] and
mesenchymal [20] origin have been shown to produce IL-6.
IL-6 production is regulated by IL-l, TNF, GM-CSF, PDGF
[24, 27], viruses [25] and bacterial endotoxin [28].
Recent work by Suematsu et al [29] established a link
between the production of IL-6 and mesangioproliferative gb-
merulonephritis in vivo. Transgenic mice carrying the human
IL-6 gene fused with a human immunoglobulin heavy chain
enhancer developed high serum concentrations of IgG 1 and
IL-6. A massive infiltration of several tissues by plasma cells
was observed as well. In addition, mesangioproliferative gb-
merulonephritis was found in histological sections of kidneys of
the transgenic mice. The authors suggest that abnormal expres-
sion of IL-6 by mesangial cells may be responsible for the
mesangioproliferative glomerulonephritis observed in these an-
imals.
Since IL-6 responsive cell-types participate in the pathogen-
esis of glomerular inflammation and since IL-6 is a pleiotropic
cytokine with effects on cells of diverse origin, we studied the
secretion of IL-6 by rat MCs as well as the effect of recombinant
IL-6 on MC proliferation in vitro. Our studies include the
biochemical characterization of rat MC-derived IL-6 as well as
the study of the effects of recombinant as well as partially
purified MC-IL-6 on proliferation of MC, which were main-
tained in a quiescent state at low serum concentration.
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Animals
Male 150 to 200 g Sprague-Dawley rats (The Charles River
Breeding Laboratories, Wilmington, Massachusetts, USA)
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were maintained in the Animal Care Facility of the VAMC,
West Haven, Connecticut, USA.
Medium and reagents
DMEM (Gibco, Grand Island, New York, USA) supple-
mented with 5 sg/ml bovine insulin (Sigma Chemical Co., St.
Louis, Missouri, USA), 50 U/ml penicillin, 50 pg/ml streptomy-
cm and 10% heat-inactivated FBS (56°C, 30 mm) was used for
culture of MCs (complete MC-medium). Human recombinant
interleukin 6 (provided by G. Wong, Genetics Institute, Cam-
bridge, Massachusetts, USA) had a specific activity of 4 x 106
U/mg. One unit was defined as stimulating half-maximal prolif-
eration of the murine plasmacytoma cell line T 1165. The rat
IL-6 cDNA probe was expressed in an expression vector
(pRIL6 C,94) after cloning [30] and used for Northern blotting
after labelling of the 900 bp insert with 32P-dCTP using random
primer extension [311. Neutralizing polyclonal rabbit anti-mu-
rine IL-6 antibody was provided by R. Nordan (NIH, Bethesda,
Maryland, USA). The anti-IL-6 antibody was used at a concen-
tration of 5 /Lg/ml. Polyclonal rabbit antihuman IL-l antibody
was purchased from Genzyme (Boston, Massachusetts, USA).
Cell lines
The murine hybridoma cell line B9, originally characterized
by Aarden Ct al [161 (Amsterdam, Netherlands), was provided
by Drs. E. Shevach and R. Nordan (NIH) and maintained in
RPMI 1640 (Whittaker Bioproducts, Inc., Walkersville, Mary-
land, USA) supplemented with 10% FBS (Hyclone Laborato-
ries, Logan, Utah, USA) 1 mr's L-glutamine, 0.05 mr's 2-
mercaptoethanol, penicillin (50 U/ml), and streptomycin (50
g/ml). The B9 cells were maintained by twice weekly feedings
using conditioned medium from freshly harvested human pe-
ripheral blood mononuclear cells in RPMI 1640 or recombinant
human IL-6.
Mesangia! cell culture
Primary cultures of MCs were obtained from outgrowths of
collagenase-treated isolated rat renal glomeruli as described
[32, 33]. Briefly, intact glomeruli were prepared by serial
sieving of cortex homogenates of blood-free kidneys. The
glomerular preparations had less than 5% tubular contamina-
tion. They were incubated with bacterial collagenase (type IV,
Sigma) for 30 minutes at 37°C, a process that results in shedding
of glomerular epithelial cells. Washed glomerular remnants,
consisting of MCs and endothelial cells, were plated at a density
of 200 to 300 remnants/cm2 in 20% FBS containing medium and
incubated at 37°C in a humidified 5% CO2 atmosphere. Under
these conditions, a homogenous outgrowth of elongated or
stellate cells appeared within seven days and reached conflu-
ency within two to three weeks. These cells are considered
vascular smooth muscle-like MCs using morphological and
immunohistochemical criteria [32, 33]. In addition, all cells
stained strongly positive with a monoclonal Thy 1.1 antibody
[33], a marker for rat MCs in kidney sections and in cell culture
[34]. Endothelial cells and resident glomerular macrophages are
not viable under the growth conditions employed. At conflu-
ence no cells stained positive for factor VIII, Ia antigen or rat
leukocyte common antigen. Fibroblast contamination was ex-
cluded by growing the MCs in D-valine containing media for
several of the early passages. Passaged MCs were obtained by
incubating washed confluent monolayers with a solution of
trypsin (0.5 mg/ml, Sigma) and EDTA (0.2 mg/mI) for five
minutes at 37°C. At this time, MCs were freed by gentle
agitation and 10% FBS medium was added. The subcultures of
MCs revealed stable morphologic and functional features [32],
and their homogeneity was repeatedly determined using immu-
nohistochemical tests as mentioned above. The techniques as
described above, which were used for isolation, identification
and culture of mesangial cells are both widely used [35] and well
established in our laboratory [32, 33, 36].
Preparation of conditioned medium (MC-CM)
Confluent monolayers of MCs in 75 cm2 flasks (Falcon,
Becton Dickinson, Oxnard, California, USA) were washed
twice with HBSS and 13 ml serum-free MC medium was added.
After three to four days of incubation the medium was collected
and spun at 400 g to remove cellular debris. CM was harvested
from MC after the sixth passage. The cell free supernatant was
concentrated 10- to 20-fold by allowing it to equilibrate in
dialysis tubing (Spectrapor No. 1, molecular wt-cutoff: 6 to
8000, Spectrum Medical md., Los Angeles, California, USA)
surrounded by polyethylene glycol compound (Sigma, molecu-
lar wt 15 to 20,000) at room temperature. The retentate was
dialyzed against deionized H20, filtered and stored at —20°C.
To achieve further concentration for biochemical characteriza-
tion of MC-CM, aliquots were dried under vacuum centrifuga-
tion and resuspended in a smaller volume of distilled H2O.
Interleukin 6 assay
IL-6 bioactivity of CM or fractions collected following elec-
trophoresis or HPLC was measured using the IL-6 dependent
murine hybridoma cell line, B9 [16, 25]. Proliferation of the B9
cells was determined by measuring the incorporation of 3H-
thymidine or using a MTF-assay as described by Mosmann [37].
For measurement of 3H-thymidine incorporation, B9 cells were
washed three times in RPMI 1640 with 10% FBS before
resuspension in fresh RPM! 1640 containing 10% FBS and
plating at a cell density of 0.2 to 1.0 x l0 cells/well in a 96-well
plate (Costar, Cambridge, Massachusetts, USA). MC-CM was
added to the wells at appropriate concentrations up to a total
volume of 0.2 mllwell. Triplicate cultures were incubated for 72
hours at 37°C in 5% CO2. Proliferation was determined by
measuring the incorporation of 3H-thymidine (1 pCi/well, spe-
cific activity: 185 GBq/mmol, 5 Ci/mmol, Amersham, Arlington
Heights, Illinois, USA), which was added during the last 18 to
24 hours. In some experiments the 3H-thymidine was added for
the last four hours of culture. The cells were harvested using an
automated cell harvester (Cambridge Technologies Inc., Cam-
bridge, Massachusetts, USA). Radioactivity was measured
with a Packard (Sterling, Virginia, USA) scintillation spectrom-
eter.
For measurement of uptake of MTT-dye 2 x io B9 cells/well
were plated in a 96-well plate and test conditions (MC-CM,
HPLC-fractions) were added in triplicate up to a total volume of
0.1 ml/well. MTT (20 p, 5 mg/ml, Sigma) was added to each
well during the last four hours of a 96-hour incubation period at
37°C, 5% CO2. After addition of 150 .d 0.04 N HCL in
2-propanol to each well, the plate was sonicated in a water bath
at room temperature for five minutes to dissolve crystals.
Absorbance was measured on an automated ELISA plate
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reader at 550 nm. Data are represented as the mean (± SD) of
triplicate determinations,
Mesangial cell proliferation assays
Mesangial cells between the sixth and twelfth passage were
used for these assays. To assess the correlation between
3H-thymidine incorporation and increase in cell number, 3H-
thymidine incorporation and cell counting were done in parallel
in three experiments. In addition, a modified MTT-assay was
used to measure cell proliferation.
For 3H-thymidine incorporation, single cell suspensions of
MC from confluent cultures were obtained by incubating
washed confluent monolayers with a solution of trypsin (0.5
mglml) and EDTA (0.2 mglml) for five minutes at 37°C. Cells (4
x 103/well) were seeded in complete MC-medium in a 96 well
plate. After adherence overnight at 37°C, 5% C02, the wells
were thoroughly washed with HBSS. MC-Medium containing
0.5% FBS was added. Four days later IL-6 suspended in
MC-medium/0.5% FBS was added to achieve final concentra-
tions of 0.1, 10, 50, 250 U/ml or IL-6. MC-medium/0.5% FBS
and complete MC-medium (containing 10% FBS) were used as
negative and positive controls, respectively. 3H-thymidine in-
corporation (1 .tCilwell) was measured during two 32-hour
intervals three days and eight days following the addition of
IL-6. At the end of the aforementioned pulse intervals the cells
were lysed by the addition of 50 pi 10 N NaOH to each well,
harvested with an automated cell harvester and radioactivity
was measured as described for the IL-6 assay. Data are
represented as the mean (± SD) of quadruplicate determina-
tions. For the MC proliferation assay of MC-CM following
RP-HPLC the same experimental set-up was used. Instead of
adding recombinant IL-6, 100 p1 aliquots of dried RP-HPLC
fractions resuspended in 1 ml of MC-mediumlO.5% FBS were
added to the MC in triplicate. 3H-thymidine incorporation was
measured at day 3.
For measurement of cell number, 4 x iO MC in complete
MC-medium were added to each well of a 24-well plate.
Adherence, washing, period of quiescence (MC-mediumlO.5%
FBS), and experimental conditions were identical to the steps
described above. MC were washed with PBS three or eight days
after the addition of IL-6. After incubation with 200 p1 trypsin/
EDTA per well for 15 minutes at 37°C/5% C02, the trypsin
reaction was stopped with 150 p1 MC-medium/20% FBS. Try-
pan blue (50 p1, 0.4%) was added to each well before aliquots of
the single cell suspension were counted using a hemocytometer.
For measurement of uptake of MTT-dye by MC the culture
conditions were identical with the conditions described above.
At day 3 and day 8, respectively, MTT assay was performed as
described earlier except that the optical density at 550 nm of
aliquots of supernatants was measured in a spectrophotometer
(Zeiss, Oberkochen, FRG).
The methods for gel filtration and reverse-phase high-pres-
sure liquid chromatography as well as granulated bed isoelectric
focusing (IEF) have been described in detail previously [33, 38].
Concentrated MC-CM was used in all assays. Collected frac-
tions were tested in the IL-6 assay, or following reverse-phase
high-pressure liquid chromatography, and used in the mesangial
cell proliferation assay as described above.
Northern blot analysis
RNA was extracted from confluent mesangial cells (fifth
passage) using acid guanidinium thiocyanate-phenol-chloro-
form [39]. After the MCs were maintained for three days in
serum free medium, FBS was added to the culture conditions
(final concentration 10% FBS) and the cells were lysed 1/2, one
and two hours later. Cells maintained in serum free medium
were used as controls. Total RNA (20 g of each condition) was
loaded on a 1% agarose-formaldehyde gel. Visualization of the
ribosomal bands under UV-light after staining with ethidium
bromide was used to assess the amount of RNA present per
lane. After electrophoresis, the RNA was transferred by pas-
sive capillary action onto nitrocellulose (0.45 /LM). The nitro-
cellulose blots were prehybridized for four hours after baking of
the nitrocellulose for two hours at 80°C, using hybridization
solution, containing 50% formamide, 5 x SSC', 200 m Na-
phosphate pH 6.5, 5 x Denhardt's solution', 0.1% SDS, 250
g/ml salmon sperm DNA. Following prehybridization, the
labeled cDNA for IL-6 (1.5 x 106 CPM/ml) was added to freshly
prepared hybridization solution and hybridization was allowed
to proceed overnight at 38°C. After two washes at room
temperature (2 x SSC, 0.1% SDS), two additional washes were
performed at 52°C for 15 minutes each (0.1 x SSC, 0.1% SDS)
and the dried blot was exposed to Kodak XAR film at —70°C for
22 hours, in a cassette with double-sided intensifying screen.
Statistical analysis
Data are expressed as mean SD. Statistical significance was
determined using the Student's two-tailed t-test.
Results
Characterization of MC-derived IL-6
To determine whether MCs produce interleukin 6, we as-
sayed concentrated (10-fold), dialyzed MC-CM for its effect on
B9 cells. As described in Methods, serial dilutions of MC-CM
were added to the B9 cells in 96-well microtiter plates and
uptake of 3H-thymidine was measured. In each of five experi-
ments, MC-CM from five different primary cultures of mesan-
gial cells between the sixth and twelfth passage induced a
dose-dependent increase in B9 cell proliferation. Control me-
dium had no effect on the proliferation of the B9 cells. Figure 1
shows results of a representative experiment. As illustrated in
Figure 1, significant B9 cell proliferation was induced in a
dose-dependent manner by concentrated (10-fold) MC-CM.
Unconcentrated MC-CM also induced B9 cell proliferation.
Production of the B9 cell proliferative factor (B9 P.F.) in-
creased within six hours after the addition of 5% FBS (data not
shown).
B9 cell proliferation is a very sensitive indicator for the
presence of interleukin 6. However, B9 cells may proliferate in
response to interleukin 4. We have previously shown that
MC-CM had no effect on the proliferation of the T-cell line
CTLL-2, which is dependent on IL-2 or IL-4 for growth and
survival [34]. While concentrated MC-CM failed to induce
Stock solutions are: 20 x SSC = 3 M NaC1, 0.3 si Na3 citrate—
2H,O, pH7; and 100 x Denhardt solution. 500 ml = 10 g Ficoll 400, 10
g polyvinylpyrrolidone, 10 g bovine serum albumin, fraction V.
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Fig. 1. Stimulation of B9 cell proliferation by MG-CM (B9 assay of
MC-CM [-U-] and control [-•-] medium). Two thousand B9 cells/well
were incubated with serial dilutions of MC-CM or control medium for
84 hours and incorporation of 3H-thymidine was measured during the
last 12 hours as described in Methods. Determinations were made in
triplicate for each dilution. Data shown are from a representative
experiment (N = 5).
proliferation of the CTLL-2 cells, aliquots of the same MC-CM
induced significant B9 cell proliferation (data not shown). Thus
the induction of proliferation of B9 cells is unlikely to be
attributable to IL-4.
To determine the molecular weight of the B9.P.F., concen-
trated MC-CM was subjected to gel filtration HPLC and the
ability of each fraction to stimulate B9 cell proliferation was
measured as described in Methods. Peak activity was found in
fractions corresponding to a molecular weight of 17 to 42 kD
(Fig. 2). Recombinant human IL-6 eluted from the same gel
filtration column with a single peak between 14 and 16 kD (data
not shown).
Horizontal isoelectric focusing of concentrated (100-fold)
MC-CM revealed several p1 forms. In three separate experi-
ments significant B9.P.F. activity was found in the pH range
between 4.0 and 5,3 (Fig. 3).
In order to compare MC-derived B9.P.F. with recombinant
human IL-6, we performed RP-HPLC of both preparations. The
B9 assay of the fractions of MC-CM collected after RP-HPLC
showed peak activity between 48% and 58% acetonitrile.
Recombinant human IL-6 eluted at 50% acetonitrile (data not
shown).
To determine whether antibody to IL-6 could block the effect
of MC-CM on B9 cells we incubated B9 cells with serial
dilutions of MC-CM in the presence or absence of rabbit
anti-murine IL-6 antibody. Polyclonal rabbit anti-murine IL-6
antibody (5 jig/ml) blocked the effects of 128-fold and 512-fold
diluted MC-CM on B9 cell proliferation (Fig. 4). This reduction
of B9 cell proliferation was statistically significant at both
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Fig. 2. Molecular weight of MC-IL-6 determined by gel filtration
HPLC. Concentrated (8-fold) MG-CM from confluent MC (8th passage)
maintained in serum free culture for three days was injected into a
Bio-Sil TSK 125 (Bio-Rad Laboratories) column using a Bio-Rad
Gradient Processor HPLC System. Fractions were assayed in the B9
assay. Elution of molecular weight standards is shown (kiloDalton).
The data shown are representative of 3 separate experiments. Standard
deviations were less than 15% of mean.
dilutions (Student's t-test). Higher dilutions of MC-CM only
marginally stimulated B9 cell proliferation. Therefore, the effect
of the antibody in suppressing this proliferative activity could
only be marginal as well and did not achieve statistical signifi-
cance. Polyclonal rabbit IgG antihuman IL-i antibody (5 p.g/ml)
did not suppress the effect of MC-CM on B9 cell proliferation.
In addition to biochemical and antigenic characterization of
the MG-derived B9 P.F., we performed Northern blot analysis
of total RNA from MC for the detection of IL-6 mRNA,
Quiescent, serum-starved MCs expressed detectable quantities
of IL-6 mRNA. Northern blot analysis of 20 jig of total RNA
revealed a predominant 1.3 kb form and a minor 2.4 kb form of
IL-6 mRNA (Fig. 5). Addition of 10% FBS to the quiescent
MCs resulted in an increase of detectable IL-6 mRNA after 60
minutes. Both forms of IL-6 mRNA were detected at 30
minutes and one and two hours following stimulation of the
cells with FBS. Visualization of the ribosomal bands after
ethidium bromide staining revealed that a smaller amount of
RNA was present in the lane representing the 30 minute
timepoint, explaining the decreased intensity of the autoradio-
graphic signal at 30 minutes compared to baseline. However,
ethidium bromide staining confirmed that all other lanes con-
tained equal amounts of RNA.
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Fig. 3. isoelectric point of MC-IL-6. Granulated bed isoelectric focus-
ing of 100-fold concentrated MC-CM was conducted as described in
Methods. Each fraction was assayed at a concentration of 25% in the B9
assay. 3H-thymidine incOrporation (3HTdR uptake) by B9 cells (open
circles) is shown in relation to the pH-gradient (filled circles) and the
fraction number. Data shown are from a representative experiment
(N = 3).
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Fig. 4. Neutralization of biological activity of MC-derived B9.P,F. by
anti-IL-6 antibody. Antimurine-IL-6 antibody (-El-; 5ig/ml) or carrier
medium (-•-; RPM! 1640 with 10% FBS) was incubated with serial
dilutions of MC-CM and 2000 B9 cells/well. 3H-thymidine incorporation
(3HTdR) was measured for each dilution in triplicate as described in
Methods. Rabbit antihuman-IL-l antibody (5 g/ml) did not affect B9
cell proliferation induced by serial dilutions of MC-CM (data not
shown). Data shown are from a representative experiment (N = 2).
Fig. 5. Expression of IL-6 mRNA by mesangial cells. Confluent MCs
(passage 5) were maintained in serum free medium for three days. RNA
was extracted at baseline (0 hours) as well as at 30 minutes, 1 hour and
2 hours following the addition of 10% FBS. Twenty micrograms of total
RNA from each time point was loaded onto an agarose-formaldehyde
gel. Following electrophoresis and staining of the gel with ethidium
bromide, the location and staining intensity of the ribosomal bands was
visualized under UV light. This revealed that the quantity of RNA in the
lane representing the 30 minute timepoint was smaller than in the other
lanes. Northern blot analysis of RNA was performed as described in
Methods. The location of the 28S and 18S ribosomal bands is indicated.
Data shown are representative of 2 experiments.
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the cells were made quiescent in medium containing 0.5% FBS.
Four days later, recombinant IL-6 (rIL-6) was added in fresh
medium containing 0.5% FBS. The effect of IL-6 on MC
proliferation was determined three and eight days later by
counting the number of MCs and measuring uptake of 3H-
thymidine and Mn' dye. As illustrated in Figure 6A, rIL-6
-
_______________________________________________ induced a dose-dependent increase of 3H-thymidine incorpora-
1/128 1/512 1/1024 1/2048 1/4096 tion. Recombinant IL-6 (250 U/mi) increased 3H-thymidine
incorporation after eight days compared to fresh medium/0.5%
FBS alone. After three days the effect of rIL-6 was less
pronounced, partially due to persistently high 3H-thymidine
incorporation of the cells cultured in medium/0.5% FBS alone
(data not shown). The number of MC and uptake of MTT dye
was also increased in response to rIL-6 (Figs. 6B, C). IL-6
induced an increase in the number of MC at day 3 which further
increased at day 8 (Fig. 7). The difference in cell number
between unstimulated and IL-6 stimulated cells was not statis-
tically significant at day 3 but reached statistical significance at
day 8. The effect of recombinant IL-6 on MC proliferation was
dependent on the presence of serum (0.5% FBS). The positive
control (FBS 10%) resulted in a rapid and more pronounced
proliferative response than that observed with rIL-6 (Fig. 7).
These results confirm that under our experimental condi-
tions, an increase in 3H-thymidine incorporation is associated
with an increase in cell number. Determination of cell number is
less sensitive than measurement of 3H-thymidine incorporation,
however, since IL-6 (250 U/mI) induced only a two- to three-
Induction of MC growth by recombinant and MC-derived IL-6
Since MC proliferation is an important component of some
forms of glomerulonephritis and since the molecular mecha-
nisms regulating MC growth are incompletely understood, we
undertook the following experiments to study the effect of IL-6
on MC growth. Confluent MC were detached with trypsin/
EDTA and seeded at low cell density (4 x 103/well in 96-well
plate, 4 x 104/well in 24 well plate). After overnight adherence
—28S
a
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Fig. 6. Growth of MC in response to recombinant IL-6. Quiescent MC
(4 X i0 MC/well) in 96-well plates (A) or 4 x 104/well in 24 well plates
(B, C) were incubated with various doses of LL-6. Eight days after the
addition of IL-6, incorporation of 3H-thymidine (A), uptake of MTT dye
(B) and cell number (C) were measured. FBS (10%) was used as a
positive control. Means of positive controls were: 12481 cpm (A), 1.621
O.D. units (B), 604 X IO cells (C). The data shown are from a
representative experiment (N = 3).
Time, days
Fig. 7. Time course of MC proliferation in response to IL-6. Quiescent
MC (4 x iO MC/well, 24 well plate) were treated with IL-6 (-•-; 250
U/mI), 10% FBS (positive control) or 0.5% FBS (-EJ-; negative control).
On days 3 and 8 the cell number in duplicate was determined as
described in Methods. The data shown are representative of 3 separate
experiments. Mean cell counts of conditions stimulated with 10% FBS
were 48.4 x l0 (day 3) and 60.4 x iO (day 8).
Table 1. partially purified MC-derived IL-6 mduces MC growtha
Fraction no. Acetonitrile IL-6 activity' MC-proliferation"
Control"
1
8
11
30
—
44.5
50
52.5
66
0
0
0.602 (0.159)
0.878 (0.001)
0
1403 (113)
5009 (3327)
8960 (915)
9027(2104)
2604 (607)
a Following separation of MC-CM using RP-HPLC, the ability of
individual fractions to induce B9 or MC proliferation was tested.
Results of representative fractions are shown.
b IL-6activity was determined using the MTT-method as described in
Methods. Activity is expressed in optical density (O.D.) with the
standard deviation of triplicate determinations shown in parentheses.
MC proliferation was determined by measuring 3H-thymidine incor-
poration 3 days after addition of RP-HPLC fractions to quiescent MC (4
x 103/well, 96 well plate). Results are expressed in mean counts per
minute (SD).
d The negative control consisted of MC-medium with 0.5% FBS.
partially purified MC-derived IL-6 to induce MC proliferation.
RP-HPLC was used to separate MC-derived IL-I and PDGF
(elute at 45% and 42% acetonitrile, respectively; unpublished
observations) from IL-6. Following elution from the RP-HPLC
column, fractions with maximal activity in the IL-6 assay
(50-55% acetonitrile) also induced MC-proliferation (Table 1).
As expected, other RP-HPLC fractions between 44 and 66%
induced MC proliferation as well, reflecting the presence of
other MC-derived factors with growth promoting activity on
MC.
A
8
200
4
0
4-'
00
0
Eà
>-I
C.,
I
I.,
100
0
0 0.1 10 50 250
Recombinant I L-6, U/mi
0.8-
B
0.6'
0.4
0.2
0 2 4 6 8 10
Recombinant I L-6, U/mi
50
200
100
Recombinant I L-6, U/mi
fold increase in cell number (Fig. 6C), whereas 3H-thymidine
incorporation was increased sixfold (Fig. 6A).
The results described above show that recombinant IL-6 is a
growth factor for MC. In order to confirm that IL-6 produced by
MCs is capable of the same effect, we measured the ability of
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Discussion
Our data show that MC produce IL-6 in culture. Our conclu-
sion is based on biochemical and antigenic characteristics of the
B9.P.F. and on the detection of IL-6 mRNA in MC. In addition,
we provide evidence that recombinant and MC-derived IL-6
induces growth of MCs.
Based on morphological and immunohistochemical criteria
(outlined in Methods) contamination of the in vitro cultures of
mesangial cells by macrophages, fibroblasts, endothelial or
epithelial cells is very unlikely [32, 33]. Furthermore, we
performed all of our experiments on cells after at least five
passages, to further insure the homogeneity of the MC culture.
No differences in MC morphology or their capacity to produce
B9 P.F. was observed between cells of different passages.
The induction of proliferation of the murine hybridoma cell
line B9 is a sensitive method for detecting IL-6 [151. Condi-
tioned medium from mesangial cells (MC-CM) induced B9 cell
proliferation in a dose-dependent fashion. As MC-CM had no
effect on 3H-thymidine uptake by the IL-4 responsive T cell line
CTLL-2 (33), the B9-proliferative factor is not likely to be
attributable to IL-4. Our data from antibody blocking experi-
ments suggest that the B9.P.F. produced by MCs shares
antigenic properties with IL-6.
In addition to functional and antigenic properties, MC-de-
rived IL-6 has biochemical properties similar to IL-6 from other
cell sources. Initial reports [19] identified IL-6 as a 26 kD
glycoprotein; however, subsequent reports have documented
the presence of multiple molecular wt forms at 14 to 19, 35 to
40, 45 and 60 to 70 kDa [40]. MC-derived IL-6 eluted from the
gel filtration column between 17 and 42 kDa. This heterogeneity
of molecular weights as compared to the molecular wt of
nonglycosylated recombinant IL-6 from E. coli (14 to 16 kDa by
gel filtration) likely reflects various degrees of 0- and N-
glycosylation of the native 184 amino acid peptide [40]. The
molecular wt of MC-derived IL-6 after gel filtration (range 17 to
42 kDa) is in good agreement with results on the molecular wt
of IL-6 from other cell sources [18, 25, 40]. Several p1 forms of
IL-6 have been reported. Shimizu, using flat-bed IEF, deter-
mined a p1 of 5 to 6 for IL-6 produced by the human trans-
formed T cell line TCL-Na 1 [41]. Using chromatofocusing the
p1 of IL-6 from the same cell line was found to be 5.0 to 5.1 [42].
The murine helper T cell clone TUC 2.15 secretes IL-6 with apI
of 5 to 6.9, which narrows to a range between 6.5 and 7.2 after
neuraminidase treatment [18]. The murine macrophage cell line
P388 D 1 secretes IL-6 with pis of 6.2 and 6.4 [17]. The different
isoelectric point forms from different cell sources may also be
attributable to variations in the extent of glycosylation of IL-6.
Alternatively, some of the differences may be attributable to the
use of different isoelectric focusing techniques. The RP-HPLC
profile of MC-IL-6 is similar to the elution profile of IL-6
secreted by TCL-Na 1 cells eluting at 55% acetonitrile [42] and
recombinant IL-6, which elutes at 50% acetonitrile.
MCs cultured in 0.5% FBS express detectable levels of IL-6
mRNA. The amount of IL-6 mRNA is rapidly enhanced after
the addition of 10% FBS. This enhanced expression of IL-6
mRNA was followed by increased IL-6 bioactivity in MC-CM
several hours following stimulation with 10% FBS (data not
shown). Our data are similar to results in other cell types, which
showed that mRNA for IL-6 in stromal cells (fibroblasts,
keratinocytes, endothelial cells) was rapidly induced by cyto-
kines, viruses, bacterial endotoxin and serum [27, 18, 43].
After detailed biochemical characterization of MC-derived
IL-6 we focused on the effect of IL-6 on MC proliferation.
Several authors have described growth promoting effects of
PDGF, IL-l and insulin-like growth factor-I (IGF-I) on mesan-
gial cells cultured in vitro [33, 44, 45]. Shultz et a! described a
dose-dependent increase in 3H-thymidine uptake by human MC
in response to increasing concentrations of PDGF [44]. The
increase in 3H-thymidine uptake correlated with an increase in
cell number after seven days of culture with PDGF. Lovett et a!
reported that three p1 forms of rat MC-derived IL-i (pls 4.45,
5.0, and 7.3) induced growth of MC [32]. The effect of IL-i on
MC growth was optimal on cells cultured in medium supple-
mented with 20% FBS. However, MC made quiescent in
medium containing 0.5% FBS and 0.5% BSA did not respond to
IL-l [32]. Recently, Horii et al [46] showed that rIL-6 enhanced
3H-thymidine uptake by rat MC in the presence of 4% FBS.
Mesangial cells maintained under serum-free conditions failed
to grow, did not contain detectable IL-6 mRNA and did not
secrete IL-6. In contrast to Horii et a! [46], we were able to
demonstrate a positive mitogenic effect of rIL-6 on quiescent
MC, which appears to be less dependent on serum than
proliferation induced by IL-i, since IL-6 induced MC growth in
the presence of 0.5% FBS. Our cell counting experiments also
show that stimulation of MC with rIL-6 does indeed result in an
increase in cell number. Whether the omission of insulin from
the culture conditions used by Horii et al is partially responsible
for the differences between their and our results is unknown.
Recent work by Doi et a! [45] supports the hypothesis that
cytokines may act at different points of the mesangial cell cycle.
PDGF may act as a competence factor during the early phase of
the cell cycle [451. Progression factors such as IGF-1 or insulin
may result in completion and acceleration of DNA synthesis.
Similarly, IL-I may act as a progression factor for MC [47]. The
site of action of IL-6 within the cell cycle of MC is not known.
Studies of the effects of IL-6 on T cells and hematopoietic cells
suggest that IL-6 may stimulate cells at G0 to enter into G1 [20,
48, 49], thereby acting as a competence factor. Since the effect
of IL-6 on MCs requires 0.5% FBS in the culture medium it
seems possible that the effect of IL-6 depends on the presence
of additional progression factors for its full effect on MC
proliferation.
Our description of IL-6 production by MCs adds to the
growing evidence that local cytokine production may be impor-
tant in the mediation of inflammation within the glomerulus.
Other authors have reported the production of IL-i, PDGF,
PAF, and GM-CSF by mesangial cells [32, 33, 50, 51].
While the presence of inflammatory cells within the glomer-
ulus has been well described in animal models of ON [4] and in
clinical specimens obtained from humans [5, 6], the mecha-
nisms leading to the accumulation of these cells within the
glomerular tuft are not well understood [1, 3]. IL-6 secreted by
MCs may play a role in the regulation of intraglomerular
cell-mediated immunity. It may be responsible, possibly in
synergy with MC-derived IL-i, for the early accumulation and
activation of T cells within the glomerulus [10, 13, 52]. The
findings reported by Horii et al [46] do suggest a role for
MC-derived IL-6 in glomerular inflammation. IL-6 was detected
by immunohistochemical staining of renal biopsies in mesangial
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cells of patients with mesangioproliferative glomerulonephntis.
Glomeruli of patients with membranous nephropathy, minimal
change nephrotic syndrome or normal kidneys stained negative
for IL-6 [46].
The factors which induce IL-6 secretion by MC are presently
unknown. In other cells IL-6 production is increased following
stimulation with IL-i, PDGF, and TNF [26, 27, 53]. Further-
more, it seems possible that IL-6 production by MCs may be
regulated by such factors as the membrane attack complex
(MAC), prostanoids or immune complexes which are impli-
cated in the pathogenesis of GN [54].
In addition to the regulation of inflammatory mechanisms
within the glomerulus, IL-6 may play a role in the regulation of
MC growth under physiologic and pathologic conditions. While
the interactions between MC-derived peptides PDGF, GM-
CSF, IGF-l, IL-i and IL-6 have not been elucidated in detail,
increased production of these cytokines during inflammatory
processes within the glomerulus may lead to increased MC
growth in vivo.
In summary, we have demonstrated that MCs produce IL-6
and have described the biochemical properties of mesangial
cell-derived IL-6. Our data also indicate that IL-6 is an auto-
crine growth factor for MCs. These findings serve as further
evidence for the regulation of the cellular immune response
within the glomerulus by MC-derived cytokines and provide an
additional basis for studies on the possible pathogenic mecha-
nisms of mesangial proliferative glomerulonephritis.
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Appendix. Abbreviations
concanavalin A
Dulbecco's modified Eagle's medium
fetal bovine serum
granulocyte macrophage-colony stimulating factor
Hanks' balanced salt solution
interleukin
mesangial cell
mesangial cell-conditioned medium
3-[4,5-dimethylthiazol(-2-yl]-2,5-diphenyltetrazolium
bromide)
phytohemagglutinin
phorbol myristate acetate
sodium dodecyl sulfate
tumor necrosis factor
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